GENinCode (LSE:GENI) Debt-to-Equity : 0.23 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode Debt-to-Equity?

GENinCode's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.08 Mil. GENinCode's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.22 Mil. GENinCode's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £1.29 Mil. GENinCode's debt to equity for the quarter that ended in Dec. 2023 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for GENinCode's Debt-to-Equity or its related term are showing as below:

LSE:GENI' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.75 Med: 0.05 Max: 0.23
Current: 0.23

During the past 5 years, the highest Debt-to-Equity Ratio of GENinCode was 0.23. The lowest was -0.75. And the median was 0.05.

LSE:GENI's Debt-to-Equity is ranked better than
50% of 194 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs LSE:GENI: 0.23

GENinCode Debt-to-Equity Historical Data

The historical data trend for GENinCode's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Debt-to-Equity Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.75

0.05

0.23

GENinCode Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			-	-	0.05	0.07	0.23

Competitive Comparison of GENinCode's Debt-to-Equity

For the Diagnostics & Research subindustry, GENinCode's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GENinCode's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where GENinCode's Debt-to-Equity falls into.

GENinCode Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

GENinCode's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.078	+	0.221)	/	1.289
	=	0.23

GENinCode's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.078	+	0.221)	/	1.289
	=	0.23

GENinCode (LSE:GENI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

GENinCode Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of GENinCode's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode (LSE:GENI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment being sale of kits and provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain and United Kingdom.